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Abstract
Purpose To assess the cost-effectiveness of Multiplex
Ligation-dependent Probe Amplification (MLPA, P095 kit)
compared to karyotyping.
Methods A cost-minimization analysis alongside a
nationwide prospective clinical study of 4,585 women
undergoing amniocentesis on behalf of their age
(C36 years), an increased risk following first trimester
prenatal screening or parental anxiety.
Results Diagnostic accuracy of MLPA (P095 kit) was
comparable to karyotyping (1.0 95% CI 0.999–1.0). Health-
related quality of life did not differ between the strategies
(summary physical health: mean difference 0.31, p = 0.82;
summary mental health: mean difference 1.91, p = 0.22).
Short-term costs were lower for MLPA: mean difference
€315.68 (bootstrap 95% CI €315.63–315.74; -44.4%). The
long-term costs were slightly higher for MLPA: mean dif-
ference €76.42 (bootstrap 95% CI €71.32–81.52; ?8.6%).
Total costs were on average €240.13 (bootstrap 95% CI
€235.02–245.23; -14.9%) lower in favor of MLPA. Cost
differences were sensitive to proportion of terminated
pregnancies, sample throughput, individual choice and
performance of tests in one laboratory, but not to failure rate
or the exclusion of polluted samples.
Conclusion From an economic perspective, MLPA is the
preferred prenatal diagnostic strategy in women who
undergo amniocentesis on behalf of their age, following
prenatal screening or parental anxiety.
On behalf of the MLPA and karyotyping (MAKE) study group.
Members of the MAKE study group are given in the Appendix.
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Introduction
In many countries, prenatal diagnosis by chorionic villus
sampling or amniocentesis is routinely offered to pregnant
women who have an increased risk of carrying a child with
a chromosomal abnormality. Amniocentesis is the most
commonly used invasive prenatal diagnostic procedure in
western countries and is performed in about one in 30
pregnancies [1, 2].
Karyotyping is considered the reference test to detect
fetal genetic abnormalities in amniotic fluid cells with
considerable accuracy [3, 4]. However, it is labor-intensive
and the costs are high. Furthermore, obtaining results takes
2–3 weeks and the extensive detection capacity of karyo-
typing can be perceived as a disadvantage due to the
detection of abnormalities with unclear or mild clinical
relevance, causing difficult counseling issues, patient anx-
iety, emotional dilemmas concerning the continuation of
pregnancy and, albeit rare, unwarranted pregnancy termi-
nations [5, 6].
Due to these disadvantages, karyotyping as a routine test
has been challenged for relatively low-risk indications. In
2003, a molecular PCR-based technique, multiplex liga-
tion-dependent probe amplification (MLPA) became
available to detect fetal aneuploidies in amniotic fluid cells
[7]. Following the results of preclinical laboratory studies,
MLPA has been proposed as a promising alternative for the
detection of the most common chromosomal aneuploidies,
i.e. trisomy 13, 18, 21 and sex chromosome aneuploidies.
Compared to karyotyping, MLPA has several potential
advantages; the waiting time for test results is reduced with
simultaneous reduction of anxiety, the preceding prenatal
counseling process can focus on the most common chro-
mosomal aneuploidies, and the technique is considerably
less labor-intensive and more suitable for high-throughput
testing, thereby exploiting economies of scale.
Nowadays, much effort has been put into priority setting
based on a trade-off of costs and health gains. From an
economic perspective, the preferred prenatal diagnostic
strategy is the one that overall yields favorable health gains
relative to associated cost differences [8].
In order to compare the MLPA and karyotyping strate-
gies in terms of diagnostic accuracy, health-related quality
of life and cost-effectiveness, we initiated a prospective
diagnostic study comparing MLPA with karyotyping in
routine clinical practice; the MLPA And Karyotyping, an
Evaluation (MAKE) study (ISRCTN47252164) [9]. If
MLPA has comparable diagnostic accuracy and is able to
reduce maternal anxiety and costs in routine clinical prac-
tice, MLPA could present a suitable substitute for karyo-
typing. Our research question was: what are the costs and
effects of MLPA compared to karyotyping when applied to
the indications advanced maternal age, increased risk fol-
lowing prenatal screening and anxiety?
Materials and methods
Clinical study
The clinical MAKE study was set up as a prospective
nationwide cohort study enrolling 4,585 consecutive
women undergoing amniocentesis for advanced maternal
age (C36 years), increased risk following prenatal screen-
ing or anxiety. Other referral indications were excluded
(e.g. ultrasound abnormalities) since these are associated
with an increased risk of a chromosomal abnormality other
than trisomies 13, 18, 21 and sex chromosome abnormal-
ities. Details of the study design have been published
elsewhere [9, 10]. In summary, after obtaining informed
consent, amniocentesis was carried out by specifically
trained obstetricians. All amniotic fluid samples were tes-
ted with both MLPA and karyotyping, allowing a pair-wise
comparison of MLPA and the reference test; karyotyping.
Sample size was estimated to demonstrate non-inferiority
(i.e. comparable diagnostic accuracy) of MLPA to karyo-
typing. During a pre-trial meeting, experts in prenatal
diagnosis, clinical epidemiology and statistics agreed on a
critical non-inferiority margin of 0.002. At least 4,497
paired test results were needed (one-sided alpha 0.05,
power 0.90) to be able to reject the null hypothesis that
MLPA is inferior to karyotyping.
MLPA
DNA was isolated from 1–8 ml uncultured amniotic fluid
samples, depending on the total amount of amniotic fluid
received. DNA was isolated from amniotic fluid cells
through lysis of cell pellets and proteinase K treatment
using standard procedures. This DNA was purified using a
QIAamp kit (Qiagen, Germany) according to the manu-
facturer’s instructions. MLPA samples were analyzed with
the commercially available SALSA MLPA P095 kit (MRC
Holland, the Netherlands). For each genomic target, a set
of two probes is designed to hybridize immediately adja-
cent to each other on the same target strand. Both probes
consist of a short target sequence and a universal poly-
merase chain reaction (PCR) primer-binding site. One of
the probes contains a stuffer sequence with a unique length
and sequence. Following hybridization, each pair of adja-
cent probes is joined by a ligation reaction. Next, PCR is
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performed using a fluorescent-labeled primer pair, which
ensures that the relative yield of each of the PCR products
is proportional to the amount of each of the target
sequences. The different length products are separated on
an automated capillary sequencer. The size and peak areas
for each probe are quantified and analyzed by data ana-
lyzing software (GeneMarker, SoftGenetics, LLC, State
College, PA, USA, or Genescan and Genemapper version
3.7/4.0, Applied Biosystems, CA, USA)[7]. Relative probe
signals are calculated and compared with samples of nor-
mal male and female sex. In chromosomally normal sam-
ples, the relative probe signal is expected to be 1 for all
probes. A normal value is defined as a relative probe signal
between 0.7 and 1.3. A relative probe value of \0.7 indi-
cates a monosomy, whereas a relative probe value of[1.3
indicates a trisomy. Technicians had a molecular genetics
or a cytogenetics background; all were trained in the exe-
cution of MLPA prior to the study onset. MLPA was
performed in duplicate, provided that at least 2 ml of
amniotic fluid was available. All eight genetic centers have
different sample throughput, depending on the number of
patients in their referring prenatal diagnostic centers.
Karyotyping
Fetal cells were cultured and karyotyped after banding.
Routinely, metaphases of at least ten colonies were
investigated. All centers followed national quality guide-
lines but minor differences in the number of cell colonies
cultured, chromosome banding and reporting of the results
were allowed [11].
Economic analysis framework
The economic analysis was performed from the societal
perspective which means that all significant costs and
health effects both in the short and long term should be
considered, regardless of who experiences the costs or the
health gains [8]. The economic evaluation was initially
designed as a cost-effectiveness analysis (CEA) [8], with
incremental costs per case of Down’s syndrome missed
by MLPA. In case of comparable diagnostic accuracy for
the detection of Down syndrome, a cost-utility analysis
(CUA) was considered the appropriate economic frame-
work, calculating the difference in costs in relation to
differences in health-related quality of life [8]. If differ-
ences in quality of life between the strategies were also
absent, a cost-minimization analysis (CMA) was carried
out. CMA implies that the preferred strategy from the
societal perspective is the one with lowest costs, since
health effects are equal [8]. We did not include a
do-nothing strategy, since the target population is eligible
for karyotyping.
Health-related quality of life
Alongside the clinical MAKE study we assessed health-
related quality of life (HRQoL) in two groups: group 1
having karyotyping and group 2 having MLPA. Included
were women with the indications maternal age, increased
risk following the findings of prenatal screening for Down
syndrome and parental anxiety. We used the MOS SF-36
health survey, measuring overall mental and overall
physical health. Mental and physical health were measured
before amniocentesis and at day 63 following amniocen-
tesis, since the SF-36 focuses on health status during the
preceding 4 weeks. Overall mental and physical health was
calculated according to accepted scoring algorithms [12].
Costs
We distinguished the costs of the MLPA and karyotyping
strategies in two components; short- and long-term costs.
The first component, the short-term costs, comprises all
societal costs that occur between amniocentesis and par-
ents’ decision to terminate or continue pregnancy. These
costs consist of the costs of the diagnostic tests and other
costs. The second component consists of the long-term
costs, i.e. all societal costs that occur between parents’
decision to terminate or continue pregnancy and lifetime
costs. Although it is controversial whether the costs asso-
ciated with chromosomal abnormalities should be included
in this type of analysis [13–15], we decided to display the
impact of missed chromosomal abnormalities on long-term
costs.
Short-term and long-term costs were further distin-
guished in direct medical costs (i.e. laboratory costs,
additional in-hospital medical costs during follow-up),
direct non-medical costs (patient expenses, e.g. patient
time and travel costs) and indirect costs (societal costs due
to absence from work) [8].
The main outcome parameters were the difference in
short-term costs between the MLPA and TKT strategies,
the long-term cost difference, and the overall cost
difference.
Short-term costs
The short-term costs consisted of the costs associated with
performing MLPA and/or karyotyping and other costs
related to the testing process. Direct medical costs of per-
formed tests were calculated as actual volumes of resource
use multiplied by the costs per unit of resource. Number
and type of tests performed were recorded in the clinical
record form or obtained by observation or questionnaire.
We used direct observations and measurements of working
time, materials, and depreciation costs of equipment to
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quantify resource use associated with MLPA. Costs per
units were obtained from a university hospital’s budgetary
and accounting system and were subsequently applied to
the resource use observed in a small and large centre. The
costs per units reflected the costs of staff, materials,
equipment, housing and departmental and hospital
overheads.
The other short-term costs consisted of additional
diagnostic tests, costs of genetic counseling in case a
chromosomal abnormality was detected, and travel costs.
Use of additional diagnostic tests was recorded in the
case record form. In case of a chromosomal abnormality,
we assumed parents visited the hospital twice for genetic
counseling [50% of cases by performed by gynecologists
(trisomies 13, 18 and 21) and 50% seen by clinical
geneticists and social workers (all other chromosomal
abnormalities)]. Travel costs per client were based on the
average travel distance to hospitals [16]. The unit costs
of direct non-medical costs were based on Dutch
guidelines [16, 17]. Short-term indirect costs did not
occur.
Study-specific costs as well as costs not associated with
diagnostic test performance (prenatal test counseling,
amniocentesis, ultrasound, sample transport, procedure-
related miscarriages) were expected to be independent of
the type of diagnostic test, and were therefore excluded
from analysis. Given the time horizon no discount rate is
used. When necessary, costs were updated to the 2007
price level by using the Dutch Consumer Price Index [18].
Long-term costs
The long-term costs were defined as the costs associated
chromosomal abnormalities and consisted of (1) incre-
mental costs for a child having a chromosomal abnormality
and (2) costs for parents of the affected child. We first
categorized chromosomal abnormalities according to clin-
ical relevance: severe consequences and other chromo-
somal abnormalities leading to severe fetal morbidity or
mortality (category I: includes trisomies 13, 18 and 21);
uncertain consequences (including sex chromosomal
abnormalities) and de novo balanced chromosomal abnor-
malities which can lead to 6% mental retardation and/or
congenital abnormalities [19] (category II); and no conse-
quences including inherited chromosomal abnormalities
and chromosomal abnormalities of known clinical irrele-
vance (category III). For category I chromosomal abnor-
malities, we used an incremental lifetime cost of €200.000
per child [20–22], a weighted average of the costs of tri-
somies 13, 18 and 21 adjusted for the average costs per
child. The costs of a category II abnormality were esti-
mated to be 6% of the costs of a child with category I
abnormality. Category III abnormalities were considered
not to induce extra costs.
Productivity loss due to absence from work in case of a
chromosomal abnormality was estimated according to the
friction cost method [16]. In case the pregnancy was
terminated, both parents were considered to have a sick
leave; on average 6 weeks for mothers and 2 weeks’
leave for partners. If the parents decided to continue the
pregnancy in case of a severe chromosomal abnormality,
the productivity loss exceeded the friction period
(22 weeks) and no extra costs beyond the friction period
were included. Assuming pregnant women to have on
average one child, working 26 h/week and aged of
25–44 years, the productivity loss is €33.60/h lost [18].
Assuming the partner to be male, aged 25–44 years old
and working fulltime, his productivity loss is on average
€40.86/h lost [18].
Sensitivity analysis
We used a sensitivity analysis to test the robustness of the
cost differences. We varied the major assumptions under-
lying the cost-effectiveness model for the following
parameters: (1) proportion of failed MLPA results,
according to the 5th and 95th percentiles of the observed
failure rate; (2) only samples with clear amniotic fluid are
analyzed with MLPA, all other samples with karyotyping;
(3) the proportion of terminated pregnancy in case of cat-
egory I chromosomal abnormalities varies from 70–80%);
(4) women are allowed individual choice: 50% of women
opts for MLPA and 50% for karyotyping [23]; (5) sample
throughput based on a small centre (n = 286) and a large
centre (n = 1,153); (6) one nationwide MLPA laboratory;
(7) all samples are analyzed with both MLPA and karyo-
typing. Parameters 1 and 5 are subject to different labo-
ratory practices. Parameter 3 might relate to societal trends,
counseling style or the counselor’s medical specialty [24].
Parameters 2, 4, 6, and 7 might change following changes
in prenatal diagnostic protocols or guidelines.
Statistical analysis
Data were recorded and analyzed by using statistical soft-
ware (SPSS version 16.0; SPSS, Chicago, Illinois).
Observed data described with descriptive statistical mea-
sures; medians with range, or mean differences with 95%
confidence intervals (CIs). Due to skewness of cost data,
the 95% CI of the mean short-term, long-term and overall
cost differences between the strategies were obtained with
the nonparametric bootstrap method, based on 10,000
bootstrap samples [25]; p value less than 0.05 (two-tailed)
was considered statistically significant.
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Results
Patients and test results
Between March 2007 and October 2008 we included 4,585
consecutively pregnant women. Patient and procedural
characteristics are displayed in Table 1. In 4,484/4,585
samples (97.8%) MLPA and karyotyping were concordant,
showing normal results in 4,387/4,585 (95.7%) and aneu-
ploidy in 98/4,585 (2.1%). Discordant results were found in
26/4,585 (0.6%) samples, representing an abnormal
karyotype undetected by MLPA. All aneuploidies of
chromosomes 13, 18, 21 and non-mosaic X and Y were
also detected by MLPA. MLPA, by design, could not
detect three severe chromosomal abnormalities other than
trisomies 13, 18, 21. In 75 cases (1.6%) the MLPA test
result failed. Karyotyping failed in one of these 75 cases
(0.02%). Diagnostic accuracy of MLPA was comparable
(non-inferior) to karyotyping (1.0 95% CI 0.999–1.0).
Sensitivity and specificity for the detection of trisomies 13,
18, 21, X and Y were 100% (95% CI 96–100%) and 100%
(95% CI 99.9–100%), respectively [11]. There were neither
statistical nor clinically relevant differences in HRQoL.
Summary physical and mental health scores between peo-
ple receiving a karyotype or MLPA did not differ (mean
difference 0.31; 95% CI -3.06 to 2.44; p 0.82 and mean
difference 1.91 95% CI -1.15 to 4.99; p 0.22, respectively)
(see Table S1). Therefore, we considered cost-minimiza-
tion analysis the appropriate framework.
Short-term costs
The test costs of the MLPA test performed in duplicate
were €344,60 per sample (65% direct and 35% overhead
costs), while the costs of karyotyping was €668,00 per
sample (74% direct and 26% overhead costs). Table 2
details the volumes of resource use, unit costs per resource
and the total short-term costs.
In the MLPA strategy, 173 subsequent karyotyping were
performed because MLPA failed (n = 75) or because
MLPA showed a chromosomal abnormality and inheri-
tance patterns needed to be examined (n = 98). Repeat
amniocentesis did not occur. MLPA was repeated in 1.6%
(5th to 95th percentile 1.3–2.1%) due to an inconclusive
result. Five subsequent FISH analyses were done: three
because MLPA showed a deletion on a single probe and the
laboratory wished to exclude a sub-microscopic deletion,
and two for a mosaic chromosome pattern (combined
mosaic pattern of Turner and Down syndrome and a
mosaic pattern for Turner syndrome and a normal female
cell line). In 22 cases in the MLPA strategy and 34 cases in
the karyotyping strategy, advanced ultrasound examination
was required to exclude other severe congenital abnor-
malities (e.g. cardiac abnormalities) in the presence of the
chromosomal abnormality to support the decision to con-
tinue or terminate the pregnancy.
In the karyotyping strategy, 11 subsequent FISH analysis
were performed for various reasons; additional information
on the grade of mosaicism (mosaic pattern Turner and Down
syndrome, mosaic pattern of Turner syndrome) (n = 2), for
marker chromosomes (n = 4), de novo unbalanced chro-
mosomal abnormalities (n = 2), a chromosomal abnor-
mality which appeared to be a normal variant (n = 2), and
for a mosaic pattern of male and female karyotype which
was determined to be a culture artefact (n = 1). In the latter
case, biochemical investigation on amniotic fluid was also
carried out to determine the testosterone/FSH ratio and
karyotyping was repeated in a postnatal sample. In 24 cases
parental karyotyping was performed to address the origin of
the chromosomal abnormality (inherited or de novo). To
assess the consequences of the de novo interstitial deletion,
MLPA on subtelomeres and a genomic micro array was
carried out. One karyotype failed due to contaminated
amniotic fluid (blood and clots). Repeat amniocentesis was
offered but the prospective parents declined.
The median short-term costs per sample, i.e. from
amniocentesis until the decision to continue or terminate
pregnancy, were €344.60 (range €344.60–3.216.08) for the
MLPA strategy and €668.00 (range €668.00–4.669.48) for
the karyotyping strategy. The short-term costs of the
MLPA strategy were on average €315.68 (bootstrap 95%
CI €315.63–315.74) lower than the karyotyping strategy
(-44.4%).
Table 1 Baseline and procedural characteristics
Median age (years) (5th to 95th%) 38.1 (31.8 to 42.4)
Indication (%)
Advanced maternal age 3,464 (75.6)
Increased risk following prenatal
screening
1,074 (23.4)
Anxiety 47 (1.0)
Median gravidity (5th to 95th%) 2 (1 to 5)
Median parity (5th to 95th%) 1 (0 to 3)
Median gestational age
(weeks ? days) (5th to 95th%)
16 ?1 (14 ? 6 to
17 ? 4)
Withdrawn amniotic fluid (median)
(5th to 95th%)
20 ml (16.0 to 20.0)
Color of amniotic fluid
Clear/yellow 4,467 (97.4%)
Red/brown/turbid/green 118 (2.6%)
Cell pellet color
White 3,923 (85.6%)
Trace of blood 381 (8.3%)
Red/brown/green, yellow, turbid 281 (6.1%)
Amniotic fluid for MLPA (median)
(5th to 95th%)
4 ml (2.0 to 8.0)
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Long-term and total costs
Table 3 displays the main volumes of resource use, the
unit costs per resource use and the long-term costs fol-
lowing the decision to continue or terminate pregnancy.
Seventy-six pregnancies in the MLPA strategy (72 clini-
cally severe, 4 clinically uncertain, 0 clinically not rele-
vant) and 79 pregnancies in the karyotyping strategy (74
clinically severe, 5 clinically uncertain, 0 clinically not
relevant) were terminated (Table S2). In two pregnancies,
postnatal karyotyping was carried out to confirm the
prenatal diagnosis (mosaic marker chromosome and
mosaic Turner).
The median long-term costs per sample, i.e. from the
decision to continue or terminate pregnancy onwards, were
€0.00 (range €0.00–233,940.00) for the MLPA strategy and
€0.00 (range €0.00 to 237,000.08) for the karyotyping
strategy (Table 2). The long-term costs of the MLPA
strategy were on average €76.42 higher compared to the
karyotyping strategy (bootstrap 95% CI €71.32–81.52;
?8.6%) per sample.
The total costs, including both short- and long-term costs,
were median €344.60 (range €344.60–237,000.08) for the
MLPA strategy and €668.00 (range €668.00–238,956.48)
for the karyotyping strategy. The total cost difference was
€240.13 (bootstrap 95% CI €235.02–€245.23) in favor of
MLPA (cost reduction -14.9%).
Sensitivity analysis
Table 4 displays the results of the sensitivity analyses.
Total MLPA costs were sensitive to the following param-
eters: the proportion of women deciding to terminate
pregnancy, women allowed individual choice, the level of
sample throughput, and performing both MLPA and kar-
yotyping. Except for the combined MLPA and karyotyping
strategy, the total costs difference remained in favor of
MLPA.
Discussion
We evaluated the cost-effectiveness of two prenatal diag-
nostic test strategies: MLPA and karyotyping. Diagnostic
accuracy of MLPA was comparable to karyotyping and
health-related quality of life was equal between strategies.
For the complete testing process, the MLPA strategy lead
to a 14.9% cost reduction per amniotic fluid sample for
women with relatively low-risk indications (-44.4% on the
short and ?8.6% on the long term).
Our study has several limitations. Firstly, we used the data
of the nationwide prospective MAKE study which priori-
tized karyotyping, since at least 12 ml of amniotic fluid was
required. The failure rate of MLPA (1.6%) may be lower
when MLPA is applied as stand-alone technique since
Table 2 Short-term costs: resource use and costs between amniocentesis and the decision to continue or terminate pregnancy
Resource use MLPA strategy
(n = 4,585)
% of total
costs MLPA
Karyotyping strategy
(n = 4,585)
% of total costs
karyotyping
Unit
costs
No No Euro
Direct costs in the hospital
Primary procedure
MLPA 4,585 87.3% 0 0.0% €344.60
Karyotyping 0 0.0% 4,585 93.98% €668.00
Additional diagnostic tests
Karyotyping 173 6.4% 0 0.0% €668.00
FISH 5 0.22% 11 0.27% €809.00
Additional diagnostic tests in case of CA
Parental karyotyping 0 0.0% 44 0.90% €668.00
DNA and/or biochemical investigation 0 0.0% 3 0.09% €934.00
Ultrasound examination (type II) 22 0.79% 34 0.68% €653.00
Outpatients visit in case of CA
Consult gynecologists (2 visits) 35 0.48% 35 0.26% €246.00
Consult clinical geneticist and social worker (2 visits) 63 4.82% 89 3.78% €1,385.00
Direct medical costs outside the hospital
Travel costs in case of CA (2 visits to hospital) 98 0.05% 124 0.04% €9.48
Total short-term costs per sample €394.93 €710.65
CA chromosomal abnormality
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MLPA requires at least 1–2 ml. Sensitivity analysis, how-
ever, showed that variations in failure rate had little impact
on the overall cost difference. Secondly, we were unable to
measure quality of life for women who decided to continue or
terminate pregnancy in case of a chromosomal abnormality
and in parents with rare prenatally undetected fetal chro-
mosomal abnormalities. However, diagnostic accuracy was
high and comparable; we can speculate that the decision to
continue or terminate pregnancy in case of a chromosomal
abnormality is the same, regardless of the diagnostic test
used. The three severe chromosomal abnormalities unde-
tected by MLPA may result in a decreased quality of life at
the individual level but not in differences at the group level.
Thirdly, we did not adjust the costs associated with pre-test
counseling. We expect that targeted testing reduces complex
counseling issues and is therefore less costly. Furthermore,
three FISH analysis were done following MLPA to exclude a
sub-microscopic deletion. If MLPA is implemented as a
stand-alone test to detect trisomies 13, 18, 21 X and Y, our
research group advises to neglect the interpretation of the
quantification of single probes. Taking this into account, the
cost reduction of MLPA compared to karyotyping may be
even larger than we estimated. Finally, costs were based on
Dutch health care costs, which might differ from costs in
other countries. That does not imply that the outcome of
MLPA being the strategy with lowest costs is not externally
valid for other countries. Hence, overall cost differences
between countries do affect the absolute cost differences, but
do not affect the ordering of strategies in terms of costs.
Compared to other RAD techniques, MLPA and quan-
titative fluorescent polymerase chain reaction (QF-PCR)
are both suitable techniques for high-throughput testing at
lower costs compared to fluorescent in situ hybridization
(FISH) [26]. A cost analysis of QF-PCR and revealed that
both tests are sensitive to sample throughput and staff skill-
mix FISH (2003) [26]. For laboratories with a throughput
of 1,000 samples per annum, karyotyping is the most
expensive test to perform, with FISH and Q-PCR calcu-
lated to incur approximately half the direct test costs of
karyotyping [26]. However, these studies did not include
long-term costs. Due to differences in methodology, a full
comparison with our study is impossible.
Costs differences were insensitive to variations in failure
rate, or using MLPA on contaminated amniotic fluid
Table 3 Long-term costs: resource use and costs after the decision to terminate or continue pregnancy
Long-term consequences MLPA strategy
(n = 4,585)
% of total
costs
Karyotyping
strategy
(n = 4,585)
% of
total costs
Unit costs
Terminated pregnancies for detected CA
Total termination of pregnancy 76 2.2% 79 2.5% €1,314,00
Clinically severe CA (T21/13/18 and other) 72 74 –
Clinically uncertain CA (X/Y and other) 4 5 –
Travel costs 76 0.01% 79 0.01% €4,74
Productivity loss for terminated pregnancies with CA 76 11.2% 79 12.9% €6,730,38
Continued pregnancies for detected CA
Clinically severe CA (T21/13/18 and other) 13 56.8% 14 68.1% €200.000,-
Clinically uncertain CA (X/Y and other) 9 2.4% 14 4.1% €12.000,-
Clinically not relevant CA (other) 0 0.0% 17 0.0% –
Confirmation of prenatal cytogenetic result after birth 0 0.0% 2 0.04% €739,72
Productivity loss for continued pregnancies with severe CA 13 9.6% 14 11.6% €33.940,-
Productivity loss for continued pregnancies with uncertain CA 9 0.4% 14 0.7% €2,036,40
Productivity loss for continued pregnancies with not relevant CA 0 0.0% 17 0.0% –
Costs for undetected chromosomal abnormalities
Other clinically severe CA 3 13.1% 0 0.0% €200.000,-
Other clinically uncertain CA 6 1.6% 0 0.0% €12.000,-
Other clinically not relevant CA 17 0.0% 0 0.0% –
Productivity loss for undetected severe CA 3 2.4% 0 0.0% €36.861,-
Productivity loss for undetected uncertain CA 6 0.3% 0 0.0% €2.211,66
Productivity loss for undetected not relevant CA 17 0.0% 0 0.0% €0,00
Total long-term costs per sample €997,85 €896,19
CA chromosomal abnormality
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samples. However, the costs of MLPA proved sensitive to
the proportion of terminated pregnancies and therefore to
societal trends, but this is unlikely to affect the overall cost
difference. Furthermore, the costs of the MLPA strategy
were sensitive to sample throughput as well as the con-
centration of MLPA analyses in one nationwide centre.
This shows that the costs and cost differences depend on
the way care is organized. Since the impact of concentra-
tion on costs was larger than the impact of higher
throughput, we recommend the use of one (or several)
nationwide MLPA laboratories. Our study also shows that
a combined strategy of MLPA followed by karyotyping is
rather inefficient. Costs are considerably increased without
any gain in diagnostic accuracy or health-related quality of
life compared to the karyotyping only strategy.
The provision of a rapid, unambiguous and a low cost
result is an incentive to implement MLPA. Successful
implementation, however, also requires the support of
pregnant women. If one supports individualized choice for
principle or other reasons [27], one could argue that the
decision to either obtain as much cytogenetic information
as possible versus a rapid but specific result on the most
common chromosomal abnormalities is most appropriately
made by individuals who will bear the responsibility for
raising the child. Our study shows that allowing individu-
alized choice—assuming that 50% chooses karyotyping
and 50% chooses MLPA [23]—also has large impact on
costs, reducing the cost difference of €240 per sample to
€83 per sample). While individual choice as strategy is less
efficient than a uniform strategy in which every patient
would receive MLPA, the overall cost reduction is still in
favor of MLPA over the current karyotyping strategy. One
could argue that offering a choice between the tests meets
most individual needs and wishes, and thereby might out-
weigh the cost difference. In a discrete choice experi-
mentation [28], women valued the comprehensive
information of karyotyping at £791 and the simple and
quick information of a Down only test at £690. This sup-
ports our idea that the option to choose may outweigh the
previously mentioned efficiency loss of €240 per sample to
€83 per sample.
Conclusion
In summary, MLPA is able to detect trisomies 13, 18, 21, X
and Y with comparable diagnostic accuracy [10, 29, 30]
and without adverse effect on quality of life at considerably
lower costs for the complete testing process. We conclude
that MLPA is the preferred strategy and recommend sub-
stitution of karyotyping for MLPA for relatively low-risk
indications. Future research should be done to evaluate
which RAD technique delivers best ‘value for money’, to
estimate the cost-effectiveness of this RAD technique on
chorionic villus biopsy, and to evaluate the most advanta-
geous organization for the optimal RAD technique.
Table 4 Sensitivity analysis: impact of parameters varied on short-term, long-term and total MLPA costs per sample (US dollars, %) compared
to baseline; and impact on the total (short term and long term) cost difference of MLPA and karyotyping
Parameter varied Short-term costs of
MLPA strategy per
sample [€ (% change)]a
Long-term costs of
MLPA strategy per
sample [€ (% change)]a
Total cost of
MLPA strategy
[€ (% change)]a
Baseline strategy 394.93 (n.a.) 997.85 (n.a.) n.a.
Failure rate
1.31% 392.75 (-0.6%) 997.85 (-) -2.19 (-0.2%)
2.05% 397.70 (?0.7%) 997.85 (-) ?2.77 (?0.2%)
Only samples with clear amniotic
fluid analyzed with MLPA
401.44 (?1.7%) 997.85 (-) ?6.50 (?0.5%)
% TOP if severe CA
80% 394.93 (-) 1,195.18 (?20.8%) ?197.33 (?14.2%)
70% 394.93 (-) 1,638.32 (?64.2%) ?640.48 (?48.7%)
Women are allowed individual choice 552.18 (?39.8%) 971.65 (-2.8%) ?131.05 (?9.4%)
Sample throughput
286 samples/year 500.55 (?26.7%) 997.85 (-) ?105.62 (?7.6%)
1,153 samples/year 374.94 (-5.1%) 997.85 (-) -19.99 (-1.4%)
One nationwide MLPA laboratory 294.68 (-29.6%) 997.85 (-) -100.25 (-7.20%)
All samples analyzed with MLPA and karyotyping 660.85 (?167.3%) 896.19 (-10.1%) ?599.19 (?43.02)
CA chromosomal abnormality, TOP termination of pregnancy
a Change compared to baseline
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Appendix
The members of the MAKE study group are: S.L. Bhola,
C.M. Bilardo, E. Birnie, E.M.A. Boormans, K. Bouman,
J. Creemers, R.J. Galjaard, A.T.T.J. Go, M.J.V. Hoffer,
A.C. Knegt, J.M.M. van Lith, M.V.E. Macville, J.G. Nijhuis,
D. Oepkes, A.C.C. van Oppen, R. Suijkerbuijk, G.H.
Schuring-Blom, A. Smits, H.I.J. Wildschut.
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